Olstein Capital Management L.P. Decreases Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Olstein Capital Management L.P. cut its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 25.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,000 shares of the company's stock after selling 9,000 shares during the quarter. Olstein Capital Management L.P. owned approximately 0.05% of Prestige Consumer Healthcare worth $2,030,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PBH. JPMorgan Chase & Co. lifted its stake in shares of Prestige Consumer Healthcare by 3.2% in the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company's stock worth $19,630,000 after acquiring an additional 8,533 shares during the period. Geode Capital Management LLC raised its holdings in Prestige Consumer Healthcare by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company's stock worth $95,678,000 after purchasing an additional 50,961 shares during the last quarter. Sequoia Financial Advisors LLC lifted its position in shares of Prestige Consumer Healthcare by 12.9% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company's stock worth $708,000 after purchasing an additional 1,120 shares during the period. Barclays PLC boosted its stake in shares of Prestige Consumer Healthcare by 346.3% in the 3rd quarter. Barclays PLC now owns 92,444 shares of the company's stock valued at $6,665,000 after purchasing an additional 71,730 shares during the last quarter. Finally, Pinnacle Associates Ltd. increased its position in shares of Prestige Consumer Healthcare by 60.3% during the third quarter. Pinnacle Associates Ltd. now owns 24,630 shares of the company's stock worth $1,776,000 after buying an additional 9,269 shares during the period. Institutional investors own 99.95% of the company's stock.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 9,885 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the sale, the senior vice president now directly owns 18,835 shares of the company's stock, valued at $1,543,904.95. This represents a 34.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the firm's stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,810 shares of company stock valued at $3,187,300. Corporate insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Stock Up 0.1 %

PBH stock traded up $0.06 during trading on Friday, reaching $76.79. 217,886 shares of the stock were exchanged, compared to its average volume of 226,830. The firm's 50 day moving average is $80.08 and its 200 day moving average is $74.93. The firm has a market cap of $3.79 billion, a P/E ratio of 18.68, a price-to-earnings-growth ratio of 2.17 and a beta of 0.51. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a twelve month low of $60.00 and a twelve month high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting analysts' consensus estimates of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same period in the prior year, the firm earned $1.07 earnings per share. Prestige Consumer Healthcare's revenue for the quarter was down .9% on a year-over-year basis. As a group, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.46 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on PBH. DA Davidson restated a "buy" rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Sidoti lowered Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price on the stock. in a research report on Monday, December 9th. Raymond James raised Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. Finally, StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $85.25.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.